false
OasisLMS
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Catalog
Advances in Thyroid Cancer
Advances in Thyroid Cancer
Advances in Thyroid Cancer
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In summary, the video transcript discusses various therapies that have the potential to impact survival in anaplastic thyroid cancer. It emphasizes the historical poor outcomes for this type of cancer and the need for aggressive treatment to improve survival rates. The transcript highlights the importance of surgeries, radiation, and cytotoxic chemotherapy in the early treatment of anaplastic thyroid cancer.<br /><br />Newer treatment options, such as multi-kinase inhibitors and immunotherapy, are also mentioned. The use of PD-1 antibodies and somatic genomic interrogation to identify targeted mutations are explored. These therapies have shown promise in improving survival rates, but further research and clinical trials are needed to fully understand their impact.<br /><br />Another topic covered in the video is the potential combination of pembrolizumab and lenvatinib in the treatment of differentiated thyroid cancer. This combination has shown impressive response rates and overall survivals in smaller trials. However, complications, particularly infectious complications, have been observed in patients who have received prior neck irradiation. The use of antimicrobial agents to minimize these complications is being explored.<br /><br />The video also discusses targeted therapies for specific genetic mutations in thyroid cancer, such as BRAF V600E and RET fusions. The use of cytotoxic treatments in conjunction with radiation and chemotherapy is explored, particularly in early stages of anaplastic thyroid cancer.<br /><br />The need for randomized therapeutic trials and early assessment of tumor mutations is emphasized. The potential use of immunotherapeutics and transcriptional targeted therapies in thyroid cancer is highlighted as areas of future research.<br /><br />Credits are given to Jenna French, Brian Haugen, the German consortium studying the combination therapy, and various organizations such as the American Thyroid Association and the International Thyroid Oncology Group.
Keywords
therapies
survival
anaplastic thyroid cancer
aggressive treatment
surgeries
radiation
cytotoxic chemotherapy
immunotherapy
PD-1 antibodies
somatic genomic interrogation
pembrolizumab
lenvatinib
BRAF V600E
×